AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33769163 — intervention group
Group type: COMPARATOR
Intervention: Parental depressive symptoms
Number of subjects: 90
Study 33769163 — intervention group
Group type: COMPARATOR
Intervention: Guilt induction
Number of subjects: 90
Study 33769163 — intervention group
Group type: COMPARATOR
Intervention: Positive parenting practices
Number of subjects: 90
Study 33769163 — intervention group
Group type: COMPARATOR
Intervention: Family cohesion
Number of subjects: 90
Study 33769163 — intervention group
Group type: COMPARATOR
Intervention: Interparental conflict
Number of subjects: 90
Study 34498946 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (400 IU/kg body wt) injection
Number of subjects: 8
Study 34498946 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 8
Study 34498946 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro incubation with rHuEPO
Number of subjects: 8
Study 34498946 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rHuEPO injection
Number of subjects: 8
Study 35281985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraparenchymal injection of placenta MSC-derived Exosome
Number of subjects: 5
Study 33165006 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate tablets (OST) - 24 tablets total, 12 tablets in the evening and 12 tablets the following morning, with 16 oz. of water with each dose and an additional 32 oz. of water with each dose.
Number of subjects: 515
Study 33165006 — intervention group
Group type: COMPARATOR
Intervention: PEG3350, electrolytes, and ascorbate (PEG‐EA) - 1 L of prep solution with 16 oz. of additional water in the evening and again in the morning.
Number of subjects: 515
Study 33165006 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate tablets (OST)
Number of subjects: 515
Study 33165006 — intervention group
Group type: COMPARATOR
Intervention: PEG3350, electrolytes, and ascorbate (PEG‐EA)
Number of subjects: 515
Study 33165006 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate tablets (OST) and PEG3350, electrolytes, and ascorbate (PEG‐EA)
Number of subjects: 515
Study 34894771 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 34894771 — intervention group
Group type: COMPARATOR
Intervention: Control (oral diazepam 5 mg and i.m. injection of pethidine)
Number of subjects: 60
Study 34894771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (acupuncture + control drugs)
Number of subjects: 60
Study 34595526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation SURfactant Extubation (InSurE)
Number of subjects: 40
Study 34595526 — intervention group
Group type: EXPERIMENTAL
Intervention: Less Invasive Surfactant Administration (LISA)
Number of subjects: 40
Study 34595526 — intervention group
Group type: COMPARATOR
Intervention: Both groups (InSurE and LISA)
Number of subjects: 40
Study 33609115 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP insertion before PCI
Number of subjects: 275
Study 33609115 — intervention group
Group type: COMPARATOR
Intervention: IABP insertion after PCI
Number of subjects: 275
Study 36273066 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 + pregabalin
Number of subjects: 112
Study 36273066 — intervention group
Group type: COMPARATOR
Intervention: Placebo + pregabalin
Number of subjects: 112
Study 33293212 — intervention group
Group type: EXPERIMENTAL
Intervention: Icenticaftor 450 mg bid for 14 days
Number of subjects: 49
Study 33293212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 33970500 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week (25-hour) mathematics Professional Development (PD) model
Number of subjects: 225
Study 32038023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemolen® ointment applied twice daily for 30 days
Number of subjects: 48
Study 34612092 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) viral load testing
Number of subjects: 150
Study 34612092 — intervention group
Group type: COMPARATOR
Intervention: Standard viral load testing (SOC)
Number of subjects: 150
Study 33624584 — intervention group
Group type: EXPERIMENTAL
Intervention: New favipiravir tablet formulation
Number of subjects: 30
Study 33624584 — intervention group
Group type: COMPARATOR
Intervention: Reference favipiravir tablet formulation
Number of subjects: 30
Study 32886923 — intervention group
Group type: EXPERIMENTAL
Intervention: Respectful family planning service provision
Number of subjects: 920
Study 32886923 — intervention group
Group type: EXPERIMENTAL
Intervention: Short acting method client
Number of subjects: 920
Study 32886923 — intervention group
Group type: EXPERIMENTAL
Intervention: Uneducated client
Number of subjects: 920
Study 32886923 — intervention group
Group type: EXPERIMENTAL
Intervention: Client with elementary education
Number of subjects: 920
Study 32886923 — intervention group
Group type: EXPERIMENTAL
Intervention: Client’s poverty
Number of subjects: 920
Study 32886923 — intervention group
Group type: EXPERIMENTAL
Intervention: Long waiting time
Number of subjects: 920
Study 32886923 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference of male service providers
Number of subjects: 920
Study 32886923 — intervention group
Group type: EXPERIMENTAL
Intervention: Service providers’ work satisfaction
Number of subjects: 920
Study 32886923 — intervention group
Group type: EXPERIMENTAL
Intervention: Health workers’ prior training on respectful care
Number of subjects: 920
Study 34871817 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based algorithm (random forest)
Number of subjects: 2325
Study 34871817 — intervention group
Group type: COMPARATOR
Intervention: Conventional TET
Number of subjects: 2325
Study 32386022 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 187
Study 34548165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg IV acetaminophen (group A)
Number of subjects: 159
Study 34548165 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg PO acetaminophen (group B)
Number of subjects: 159
Study 34548165 — intervention group
Group type: COMPARATOR
Intervention: IV and PO placebo (group C)
Number of subjects: 159
Study 34548165 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 159
Study 33260144 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal proprioceptive exercise
Number of subjects: 19
Study 33260144 — intervention group
Group type: COMPARATOR
Intervention: Yoga
Number of subjects: 19
Study 33260144 — intervention group
Group type: COMPARATOR
Intervention: Classroom-based control
Number of subjects: 19
Study 32693842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical and psychological BOOST group physiotherapy programme
Number of subjects: 0
Study 32693842 — intervention group
Group type: COMPARATOR
Intervention: Best practice advice (Control)
Number of subjects: 0
Study 36288445 — intervention group
Group type: EXPERIMENTAL
Intervention: FICare intervention
Number of subjects: 13
Study 36288445 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 13
Study 32174342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic assembly under four conditions (line‐type, batch‐type)
Number of subjects: 15
Study 616840380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraorbital electroacupuncture therapy
Number of subjects: 60
Study 616840380 — intervention group
Group type: COMPARATOR
Intervention: Neural nutrition drug (given to both groups)
Number of subjects: 60
Study 36921715 — intervention group
Group type: COMPARATOR
Intervention: BNT161b2/30μg
Number of subjects: 122
Study 36921715 — intervention group
Group type: EXPERIMENTAL
Intervention: monovalent-Omi.BA.1/30μg
Number of subjects: 122
Study 36921715 — intervention group
Group type: EXPERIMENTAL
Intervention: monovalent-Omi.BA.1/60μg
Number of subjects: 122
Study 36921715 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent-Omi.BA.1/30μg
Number of subjects: 122
Study 36921715 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent-Omi.BA.1/60μg
Number of subjects: 122
Study 33560089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Number of subjects: 150
Study 33560089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 36221431 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management coaching
Number of subjects: 109
Study 36221431 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 109
Study 32918079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use >60 days/year
Number of subjects: 12101
Study 32918079 — intervention group
Group type: COMPARATOR
Intervention: Aspirin use ≤60 days/year
Number of subjects: 12101
Study 33559061 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiologic information inserted into spine imaging reports
Number of subjects: 170680
Study 32522263 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-based centralized monitoring group
Number of subjects: 114
Study 32522263 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 34328060 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential reinforcement of approximations
Number of subjects: 3
Study 34328060 — intervention group
Group type: COMPARATOR
Intervention: Terminal reinforcement
Number of subjects: 3
Study 32534120 — intervention group
Group type: EXPERIMENTAL
Intervention: GeGen Decoction
Number of subjects: 30
Study 32534120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35493824 — intervention group
Group type: EXPERIMENTAL
Intervention: t-DCS (n = 13) for 5 daily sessions (20 min−2 mA) with bi-hemispheric stimulation over the primary motor cortex (M1)
Number of subjects: 28
Study 35493824 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n = 15) with the same duration and cadence
Number of subjects: 28
Study 36217190 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cooling permitted during passive exposure to humid heat
Number of subjects: 10
Study 33720895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) for 12 weeks
Number of subjects: 56
Study 32345452 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with suboccipital muscle inhibition and interferential current (20 minutes, twice weekly for 4 weeks)
Number of subjects: 25
Study 32345452 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 25
Study 34571194 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) only for patients (Arm 1)
Number of subjects: 510
Study 34571194 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) for patients and caregivers (Arm 2)
Number of subjects: 510
Study 34571194 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Arm 3)
Number of subjects: 510
Study 34275476 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus fosinopril
Number of subjects: 200
Study 34275476 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study 35552513 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol (1000 mg)
Number of subjects: 110
Study 35552513 — intervention group
Group type: COMPARATOR
Intervention: IM tramadol (100 mg)
Number of subjects: 110
Study 34431879 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricant eyedrops from five different brands
Number of subjects: 5
Study 34431879 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laboratory equipment for measuring eyedrop mass
Number of subjects: 5
Study 33633687 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in daily GH dose (IGF-1 target level of 1 to 2 SDS)
Number of subjects: 32
Study 33633687 — intervention group
Group type: COMPARATOR
Intervention: Decrease in daily GH dose (IGF-1 target level of -2 to -1 SDS)
Number of subjects: 32
Study 32571329 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified short-term fasting (mSTF)
Number of subjects: 30
Study 32571329 — intervention group
Group type: COMPARATOR
Intervention: Ketogenic diet (KD) as fasting supportive diet
Number of subjects: 30
Study 35535532 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation, treated once every other day for 4 weeks.
Number of subjects: 120
Study 35535532 — intervention group
Group type: COMPARATOR
Intervention: Eperisone hydrochloride tablets combined with TSLO brace, oral eperisone hydrochloride tablets 50 mg three times a day, wearing TSLO brace for not less than 8 hours a day for 4 weeks.
Number of subjects: 120
Study 32372277 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol at 1 μg/kg/min
Number of subjects: 150
Study 32372277 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol at 2 μg/kg/min
Number of subjects: 150
Study 32372277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no landiolol)
Number of subjects: 150
Study 33213202 — intervention group
Group type: EXPERIMENTAL
Intervention: cVEMP test in psoriasis patients
Number of subjects: 43
Study 33213202 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOAE test in psoriasis patients
Number of subjects: 43
Study 33213202 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 43
Study 34216177 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA (single dose of oral netupitant/palonosetron)
Number of subjects: 0
Study 34216177 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant (3-day regimen)
Number of subjects: 0
Study 34216177 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA
Number of subjects: 0
Study 34216177 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant
Number of subjects: 0
Study 32692701 — intervention group
Group type: EXPERIMENTAL
Intervention: Anise (Pimpinella Anisum) 110 mg capsules three times a day (total 330 mg/day)
Number of subjects: 67
Study 32692701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch capsules)
Number of subjects: 67
Study 36121830 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic medication review conducted by clinical pharmacists during emergency department stay.
Number of subjects: 789
Study 36121830 — intervention group
Group type: COMPARATOR
Intervention: Standard care from emergency department physicians and nurses (Control group).
Number of subjects: 789
Study 33092803 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (post‐tetanic count 1–2 twitches)
Number of subjects: 98
Study 33092803 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block (train‐of‐four 1–2 twitches)
Number of subjects: 98
Study 33092803 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Number of subjects: 98
Study 33092803 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block
Number of subjects: 98
Study 35114667 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (group A1)
Number of subjects: 27
Study 35114667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech vaccine (group B1)
Number of subjects: 27
Study 35114667 — intervention group
Group type: COMPARATOR
Intervention: Control group for CoronaVac (group A2)
Number of subjects: 27
Study 35114667 — intervention group
Group type: COMPARATOR
Intervention: Control group for Pfizer-BioNTech (group B2)
Number of subjects: 27
Study 33212111 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training 3 times/week for 6 months
Number of subjects: 18
Study 33212111 — intervention group
Group type: COMPARATOR
Intervention: Control group (Untrained)
Number of subjects: 18
Study 32150078 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT)
Number of subjects: 2280
Study 32150078 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) alone
Number of subjects: 2280
Study 35022545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (nutrition education, physical education)
Number of subjects: 154
Study 35022545 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study 34841935 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-Friendly Hospital Initiative
Number of subjects: 131
Study 33618281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (LPV) with ECCO2R when PaCO2 > 55 mmHg
Number of subjects: 0
Study 33618281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-LPV with ECCO2R for all
Number of subjects: 0
Study 33618281 — intervention group
Group type: COMPARATOR
Intervention: Lung protective ventilation (LPV) with ECCO2R
Number of subjects: 0
Study 33618281 — intervention group
Group type: COMPARATOR
Intervention: Ultra-LPV with ECCO2R
Number of subjects: 0
Study 33618281 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation (MV)
Number of subjects: 0
Study 33270038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-vaccine posts (n=324)
Number of subjects: 580
Study 33270038 — intervention group
Group type: COMPARATOR
Intervention: Anti-vaccine posts (n=256)
Number of subjects: 580
Study 33270038 — intervention group
Group type: COMPARATOR
Intervention: Antivaccine misinformation characteristics
Number of subjects: 580
Study 33270038 — intervention group
Group type: COMPARATOR
Intervention: Information/resource posts
Number of subjects: 580
Study 33270038 — intervention group
Group type: COMPARATOR
Intervention: Personal narrative posts
Number of subjects: 580
Study 33270038 — intervention group
Group type: EXPERIMENTAL
Intervention: Most liked pro-vaccine post
Number of subjects: 580
Study 33270038 — intervention group
Group type: COMPARATOR
Intervention: Most liked anti-vaccine post
Number of subjects: 580
Study 34747516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (4000 IU/d)
Number of subjects: 193
Study 34747516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 35568638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal tube stabilization (NTS) with wire-reinforced tube
Number of subjects: 24
Study 35568638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal tube stabilization (NTS) with RAE tube
Number of subjects: 24
Study 35568638 — intervention group
Group type: COMPARATOR
Intervention: Wire-reinforced tube (before NTS)
Number of subjects: 24
Study 35568638 — intervention group
Group type: COMPARATOR
Intervention: RAE tube (before NTS)
Number of subjects: 24
Study 33223228 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Lidocaine Patch (LP)
Number of subjects: 57
Study 33223228 — intervention group
Group type: COMPARATOR
Intervention: Placebo Patch
Number of subjects: 57
Study 35307066 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP combined with inhalation of pulmonary surfactant using vibrating mesh nebulizers
Number of subjects: 42
Study 35307066 — intervention group
Group type: COMPARATOR
Intervention: NCPAP combined with inhalation of pulmonary surfactant using endotracheal tube (INSURE)
Number of subjects: 42
Study 34344839 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine solution
Number of subjects: 55
Study 34344839 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 55
Study 34344839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Octenidine and Saline)
Number of subjects: 55
Study 34644432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 7
Study 35050943 — intervention group
Group type: EXPERIMENTAL
Intervention: Weierkang pills
Number of subjects: 108
Study 35050943 — intervention group
Group type: COMPARATOR
Intervention: Folic acid combined with teprenone
Number of subjects: 108
Study 33430937 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE) with linear stapled anastomosis
Number of subjects: 20
Study 33430937 — intervention group
Group type: COMPARATOR
Intervention: Open esophagectomy (OE) with circular stapled anastomosis
Number of subjects: 20
Study 32458393 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative Sinusectomy
Number of subjects: 0
Study 32458393 — intervention group
Group type: COMPARATOR
Intervention: Excision and primary off-midline closure
Number of subjects: 0
Study 33278293 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 78
Study 33278293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 32460523 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 15 mg/day
Number of subjects: 473
Study 32460523 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 30 mg/day
Number of subjects: 473
Study 32460523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 473
Study 32460523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study 35038433 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus trastuzumab
Number of subjects: 203
Study 35038433 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy alone
Number of subjects: 203
Study 34802328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (experimental group)
Number of subjects: 189
Study 34802328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 189
Study 32467546 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (Metformin/Glibenclamide 500mg/5mg)
Number of subjects: 28
Study 32467546 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (Metformin/Glibenclamide 500mg/5mg)
Number of subjects: 28
Study 36132088 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB-based training intervention (8 training sessions)
Number of subjects: 87
Study 36132088 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (nutritional and physical activity recommendations)
Number of subjects: 87
Study 33511201 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TXA (3 g of TXA in 100 mL saline after TKA)
Number of subjects: 103
Study 33511201 — intervention group
Group type: COMPARATOR
Intervention: Topical Floseal® (10 mL of Floseal® intra-articularly during surgery)
Number of subjects: 103
Study 33511201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intra-articular saline injection only)
Number of subjects: 103
Study 36266762 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab 600 mg IV
Number of subjects: 1881
Study 36266762 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab 1200 mg IV
Number of subjects: 1881
Study 36266762 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab 180 mg SC
Number of subjects: 1881